# US 2008/0187911 A1 · Methods and compositions for analysis of mitochondrial-related gene expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187911 A1
- Document ID: US20080187911A1
- Status: Published application
- Kind: A1
- Application number: 10/767,217
- Filed: 2004-01-29
- Published: 2008-08-07
- Earliest claimed: 2003-01-30
- Assignees: Research Development Foundation
- Inventors: John Papaconstantinou; James Deford; Arpad Gerstner
- Web page: https://patentgrep.com/patent/US20080187911A1

## CPC

- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention provides arrays for analyzing the expression of mitochondrial-related coding sequences. The invention allows the efficient analysis of expression levels across each of these coding sequences. The invention has important applications in the field of medicine for the screening and diagnosis of patients with ailments associated with aberrant mitochondrial function, as well as in the development of treatments therefore.

## Claims

### Claim 1

An array comprising nucleic acid molecules comprising a plurality of sequences, wherein the molecules are immobilized on a solid support and wherein at least 5% of the immobilized molecules are capable of hybridizing to mitochondrial-related nucleic acid sequences or complements thereof.

### Claim 2 (depends on 1)

The array of claim 1, further defined as comprising at least 20 nucleic acid molecules.

### Claim 3 (depends on 1)

The array of claim 1, further defined as comprising at least 40 nucleic acid molecules.

### Claim 4 (depends on 1)

The array of claim 1, further defined as comprising at least 100 nucleic acid molecules.

### Claim 5 (depends on 1)

The array of claim 1, further defined as comprising at least 200 nucleic acid molecules.

### Claim 6 (depends on 1)

The array of claim 1, further defined as comprising at least 400 nucleic acid molecules.

### Claim 7 (depends on 1)

The array of claim 1, wherein said nucleic acid molecules comprise cDNA sequences.

### Claim 8 (depends on 1)

The array of claim 1, wherein each of said nucleic acid molecules comprises at least 17 nucleotides.

### Claim 9 (depends on 1)

The array of claim 1, wherein the mitochondrial-related nucleic acid sequences are from a mammal.

### Claim 10 (depends on 9)

The array of claim 9, wherein the mitochondrial-related nucleic acid sequences are from a primate.

### Claim 11 (depends on 9)

The array of claim 9, wherein the mitochondrial-related nucleic acid sequences are from a human.

### Claim 12 (depends on 9)

The array of claim 9, wherein the mitochondrial-related nucleic acid sequences are from a yeast.

### Claim 13 (depends on 9)

The array of claim 9, wherein the mitochondrial-related nucleic acid sequences are from a mouse.

### Claim 14 (depends on 9)

The array of claim 9, wherein the mitochondrial-related nucleic acid sequences are from Drosophila.

### Claim 15 (depends on 9)

The array of claim 9, wherein the mitochondrial-related nucleic acid sequences are from the nematode, C. elegans.

### Claim 16 (depends on 1)

The array of claim 1, wherein at least 25% of the immobilized molecules are capable of hybridizing to mitochondrial-related nucleic acid sequences or complements thereof.

### Claim 17 (depends on 1)

The array of claim 1, wherein at least 35% of the immobilized molecules are capable of hybridizing to mitochondrial-related nucleic acid sequences or complements thereof.

### Claim 18 (depends on 1)

The array of claim 1, wherein at least 50% of the immobilized molecules are capable of hybridizing to mitochondrial-related nucleic acid sequences or complements thereof.

### Claim 19 (depends on 1)

The array of claim 1, wherein at least 75% of the immobilized molecules are capable of hybridizing to mitochondrial-related nucleic acid sequences or complements thereof.

### Claim 20 (depends on 1)

The array of claim 1, wherein at least 85% of the immobilized molecules are capable of hybridizing to mitochondrial-related nucleic acid sequences or complements thereof.

### Claim 21 (depends on 1)

The array of claim 1, wherein at least 95% of the immobilized molecules are capable of hybridizing to mitochondrial-related nucleic acid sequences or complements thereof.

### Claim 22 (depends on 1)

The array of claim 1, wherein 100% of the immobilized molecules are capable of hybridizing to mitochondrial-related nucleic acid sequences or complements thereof.

### Claim 23 (depends on 1)

The array of claim 1, wherein at least one of said mitochondrial-related nucleic acid sequences is encoded by a mitochondrial genome.

### Claim 24 (depends on 1)

The array of claim 1, wherein the immobilized molecules are capable of hybridizing to at least 5 mitochondrial-related nucleic acid sequences or complements thereof.

### Claim 25 (depends on 1)

The array of claim 1, wherein the immobilized molecules are capable of hybridizing to at least 10 mitochondrial-related nucleic acid sequences or complements thereof.

### Claim 26 (depends on 1)

The array of claim 1, wherein the immobilized molecules are capable of hybridizing to at least 13 mitochondrial-related nucleic acid sequences or complements thereof.

### Claim 27 (depends on 1)

The array of claim 1, wherein the immobilized molecules are capable of hybridizing to at least 20 mitochondrial-related nucleic acid sequences or complements thereof.

### Claim 28 (depends on 1)

The array of claim 1, wherein the immobilized molecules are capable of hybridizing to at least 30 mitochondrial-related nucleic acid sequences or complements thereof.

### Claim 29 (depends on 1)

The array of claim 1, wherein the immobilized molecules are capable of hybridizing to at least 60 mitochondrial-related nucleic acid sequences or complements thereof.

### Claim 30 (depends on 1)

The array of claim 1, wherein the immobilized molecules are capable of hybridizing to at least 100 mitochondrial-related nucleic acid sequences or complements thereof.

### Claim 31 (depends on 1)

The array of claim 1, wherein the immobilized molecules are capable of hybridizing to at least 200 mitochondrial-related nucleic acid sequences or complements thereof.

### Claim 32 (depends on 1)

The array of claim 1, wherein the immobilized molecules are capable of hybridizing to at least 300, at least 500, or at least 1000 mitochondrial-related nucleic acid sequences or complements thereof.

### Claim 33 (depends on 1)

The array of claim 1, wherein at least one of said mitochondrial-related nucleic acid sequences is encoded by a nuclear genome.

### Claim 34 (depends on 1)

The array of claim 1, wherein at least one of said mitochondrial-related nucleic acid sequences is encoded by a mitochondrial genome.

### Claim 35 (depends on 1)

A method for measuring the expression of one or more mitochondrial-related coding sequence in a cell or tissue, said method comprising:
a) contacting an array according to claim 1 with a sample of nucleic acids from the cell or tissue under conditions effective for mRNA or complements thereof from said cell or tissue to hybridize with the nucleic acid molecules immobilized on the solid support; and
b) detecting the amount of mRNA or complements thereof hybridizing to mitochondrial-related nucleic acid sequences or complements thereof.

### Claim 36 (depends on 35)

The method of claim 35, wherein said detecting is carried out calorimetrically, fluorometrically, or radiometrically.

### Claim 37 (depends on 35)

The method of claim 35, wherein the cell is a mammal cell.

### Claim 38 (depends on 35)

The method of claim 35, wherein the cell is a primate cell.

### Claim 39 (depends on 35)

The method of claim 35, wherein the cell is a human cell.

### Claim 40 (depends on 35)

The method of claim 35, wherein the cell is a mouse cell.

### Claim 41 (depends on 35)

The method of claim 35, wherein the cell is a yeast cell.

### Claim 42 (depends on 1)

A method of screening an individual for a disease state associated with altered expression of one or more mitochondrial-related nucleic acid sequences comprising:
a) contacting an array according to claim 1 with a sample of nucleic acids from the individual under conditions effective for the mRNA or complements thereof from said individual to hybridize with the nucleic acid molecules immobilized on the solid support;
b) detecting the amount of mRNA or complements thereof hybridizing to mitochondrial-related nucleic acid sequences; and
c) screening the individual for a disease state by comparing the expression of said mitochondrial-related nucleic acid sequences detected with a pattern of expression of said mitochondrial-related nucleic acid sequences associated with said disease state.

### Claim 43 (depends on 42)

The method of claim 42, wherein said disease state is a disease state as listed in Table 1.

### Claim 44 (depends on 43)

The method of claim 43, wherein the disease state is cystic fibrosis, Alzheimer's disease, Parkinson's disease, ataxia, diabetes mellitus, multiple sclerosis or cancer.

### Claim 45 (depends on 42)

The method of claim 42, wherein said detecting is carried out calorimetrically, fluorometrically, or radiometrically.

### Claim 46 (depends on 42)

The method of claim 42, wherein the individual is a mammal.

### Claim 47 (depends on 42)

The method of claim 42, wherein the individual is a primate.

### Claim 48 (depends on 42)

The method of claim 42, wherein the individual is a human.

### Claim 49 (depends on 42)

The method of claim 42, wherein the individual is a mouse.

### Claim 50 (depends on 42)

The method of claim 42, wherein the individual is a an arthropod.

### Claim 51 (depends on 42)

The method of claim 42, wherein the individual is a nematode.

### Claim 52 (depends on 1)

A method of screening a compound for its affect on mitochondrial structure and/or function comprising:
a) contacting an array according to claim 1 with a sample of nucleic acids from a cell under conditions effective for the mRNA or complements thereof from said cell to hybridize with the nucleic acid molecules immobilized on the solid support, wherein the cell has previously been contacted with said compound under conditions effective to permit the compound to have an affect on mitochondrial structure and/or function;
b) detecting the amount of mRNA encoded by mitochondrial-related nucleic acid sequences or complements thereof that hybridizes with the nucleic acid molecules immobilized on the solid support; and
c) correlating the detected amount of mRNA encoded by mitochondrial-related nucleic acid molecules or complements thereof with the affect of the compound mitochondrial structure and/or function.

### Claim 53 (depends on 52)

The method of claim 52, wherein the compound is a small molecule.

### Claim 54 (depends on 52)

The method of claim 52, wherein the compound is formulated in a pharmaceutically acceptable carrier or diluent.

### Claim 55 (depends on 52)

The method of claim 52, wherein the compound is an oxidative stressing agent or an inflammatory agent.

### Claim 56 (depends on 52)

The method of claim 52, wherein the compound is a chemotherapeutic agent.

### Claim 57 (depends on 52)

The method of claim 52, wherein said detecting is carried out calorimetrically, fluorometrically, or radiometrically.

### Claim 58 (depends on 1)

A method for screening an individual for reduced mitochondrial function comprising:
a) contacting an array according to claim 1 with a sample of nucleic acids from a cell under conditions effective for the mRNA or complements thereof from said cell to hybridize with the nucleic acid molecules immobilized on the solid support;
b) detecting the amount of mRNA encoded by mitochondrial-related nucleic acid sequences or complements thereof that hybridizes with the nucleic acid molecules immobilized on the solid support; and
c) correlating the detected amount of mRNA or complements thereof with reduced mitochondrial function.

### Claim 59 (depends on 58)

The method of claim 58, wherein said detecting is carried out calorimetrically, fluorometrically, or radiometrically.

### Claim 60 (depends on 58)

The method of claim 58, wherein the individual is a mammal.

### Claim 61 (depends on 58)

The method of claim 58, wherein the individual is a primate.

### Claim 62 (depends on 58)

The method of claim 58, wherein the individual is a human.

### Claim 63 (depends on 58)

The method of claim 58, wherein the individual is a mouse.

### Claim 64 (depends on 58)

The method of claim 58, wherein the individual is an arthropod.

### Claim 65 (depends on 58)

The method of claim 58, wherein the individual is a nematode.
